Israel Active

Israel’s UroGen Pharma (see previously) has published positive results from two clinical trials of bladder cancer treatment UGN-102. The therapy can benefit some 80,000 patients. Trial success (65%) was similar to patients who had surgery but with a 55% less re-occurrence rate.

A woman with Stevens-Johnson Syndrome (SJS) was saved by doctors at Soroka-University Medical Center in Beersheba. The genetic disease progresses into toxic epidermal necrolysis – a life threatening condition causing 30% of the skin to peel off.

Israel’s Pharma Two B (see previously) is presenting the full results of its Phase 3 trial of its once-a-day injection of its P2B001 treatment for Parkinson’s disease. P2B001 combines low-dose pramipexole with low-dose rasagiline. It relieves PD symptoms with few side effects.

Sheba Medical Center has deployed a new accelerated, AI-powered cancer diagnostics research platform to improve patient diagnosis, treatment, and outcomes. It utilizes solutions of various Israeli startups, including that of Imagene (see previously).

Healthcare app Together by Renee is integrating the video-based biomarker check technology from Israel’s Binah.ai (see previously). The platform allows US seniors to easily check and share vital signs with caregivers and family, using their smartphone cameras.

Joint Israeli & US research has revealed crucial insights into the early development of specialized tissues that protect the fetus during human pregnancy. The findings can potentially help prevent dangerous pregnancy complications, like pre-eclampsia and preterm birth.

Israel’s Sofwave Medical (see previously) has received US FDA approval for its treatment for acne scars. 88% of patients reported an improvement in a clinical study of Sofwave’s Synchronous Ultrasound Parallel Beam (SUPERB) technology.

Israel’s Neurosteer (see previously) has developed a musical test for the early detection of Parkinson’s Disease as well as Alzheimer’s and other forms of dementia.  Patients conduct a series of musical tasks while sensors connected to an EEG device record their brain activity.

Israel’s BioProtect (see previously) has received US FDA's clearance for its biodegradable balloon spacer that protects healthy tissue against damage during prostate cancer radiation therapy.  BioProtect already has approval for the European market.

Researchers at Israel’s Ariel University have enhanced the ability of Photodynamic cancer therapy (PDT) to reach tumors deep inside the body. They used nanoparticles of barium titanate, curcumin (turmeric) and pulsed lasers to optimize the Near Infrared Light.